Company: JUNS
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001641172-25-024684
Chunk: 1

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-08-19
Form: 10-Q
Item: Item 8
Chunk 1
---
 Public Offering, the Company’s common stock began trading on The Nasdaq Capital Market under the symbol “JUNS.”

Nasdaq
Minimum Bid Price Compliance

On
March 21, 2025, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the
Company was not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), which requires listed securities
to maintain a minimum closing bid price of $1.00 per share for at least 30 consecutive business days. Based on the 30 consecutive business
days from February 6, 2025 through March 20, 2025, the Company’s common stock failed to meet this requirement.

Pursuant
to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until September 17, 2025, to regain compliance by
maintaining a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.

On
July 9, 2025, the Company received written confirmation from Nasdaq that it had regained compliance with Listing Rule 5550(a)(2), as
the closing bid price of its common stock had been at or above $1.00 per share for 13 consecutive business days (June 18, 2025 through
July 8, 2025).

    8

JUPITER
NEUROSCIENCES, INC.

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June
30, 2024

Note
2 – Significant Accounting Policies

Basis
of presentation, Liquidity and Management’s Plans

The
accompanying condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally
accepted in the United States of America (“U.S. GAAP”). U.S GAAP contemplates the continuation of the Company as a going
concern. The Company has had no revenues from product sales since inception and incurred a net loss of $3,781,832 and had negative cash
flows of operations totaling $1,891,263 for the six months ended June 30, 2025, and a cumulative net loss since inception totaling $29,803,961.

In management’s
opinion, these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at
least twelve months